NATALEE 6-year analysis demonstrated an OS benefit with adjuvant ribociclib in HR+/HER2− early breast cancer (HR 0.81; absolute benefit 2.1%), with sustained iDFS benefit (HR 0.74;

Kazuki Nozawa, MD· @kazuki_nozawa · X·2026-10-23 20:49· 2 天前评分70

正文 · 原文

NATALEE 6-year analysis demonstrated an OS benefit with adjuvant ribociclib in HR+/HER2− early breast cancer (HR 0.81; absolute benefit 2.1%), with sustained iDFS benefit (HR 0.74; absolute benefit 5.3%).
#ESMO26

781 浏览 · 8 赞 · 2 转发 · 0 回复

会议摘要

LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

来源：Kazuki Nozawa, MD · x.com